PMID- 14992418
OWN - NLM
STAT- MEDLINE
DCOM- 20040517
LR  - 20191108
IS  - 1098-3597 (Print)
IS  - 1873-4480 (Linking)
VI  - Suppl 3
DP  - 2003
TI  - Safety and tolerability of fluoroquinolones.
PG  - S29-36
AB  - Clinical trials in patients with community- and hospital-acquired infections have 
      established that the clinical effectiveness and safety of fluoroquinolones are 
      similar to beta-lactam and macrolide agents. The most common drug-related adverse 
      effects (AEs) with fluoroquinolone therapy involve the gastrointestinal tract and 
      central nervous system and are usually transient and mild to moderate in 
      severity. However, serious toxic reactions have led to the limited and 
      restrictive use of trovafloxacin in the United States and the withdrawal of 
      temafloxacin and grepafloxacin from worldwide markets. In addition, postmarketing 
      spontaneous AE reports have imposed updates in the precautions and warning 
      sections of product package inserts of selected fluoroquinolones. This article 
      reviews the AEs associated with the fluoroquinolones and compares the safety 
      profiles of ciprofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.
FAU - Sprandel, Kelly A
AU  - Sprandel KA
AD  - University of Illinois at Chicago, Illinois 60612, USA.
FAU - Rodvold, Keith A
AU  - Rodvold KA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Cornerstone
JT  - Clinical cornerstone
JID - 9816002
RN  - 0 (Blood Glucose)
RN  - 0 (Fluoroquinolones)
SB  - IM
MH  - Anaphylaxis/chemically induced
MH  - Blood Glucose/drug effects
MH  - Central Nervous System/drug effects
MH  - Community-Acquired Infections/*drug therapy
MH  - Cross Infection/*drug therapy
MH  - Digestive System/drug effects
MH  - Drug Tolerance
MH  - Fluoroquinolones/*adverse effects/pharmacology
MH  - Humans
MH  - Kidney/drug effects
MH  - Liver/drug effects
MH  - Musculoskeletal System/drug effects
MH  - Safety
RF  - 37
EDAT- 2004/03/03 05:00
MHDA- 2004/05/18 05:00
CRDT- 2004/03/03 05:00
PHST- 2004/03/03 05:00 [pubmed]
PHST- 2004/05/18 05:00 [medline]
PHST- 2004/03/03 05:00 [entrez]
AID - S1098-3597(03)90027-5 [pii]
AID - 10.1016/s1098-3597(03)90027-5 [doi]
PST - ppublish
SO  - Clin Cornerstone. 2003;Suppl 3:S29-36. doi: 10.1016/s1098-3597(03)90027-5.